Problems of intensive therapy in childhood cancer.
Tremendous progress has been made in the treatment of childhood cancers. Certain hematologic malignancies have an impressive cure rate with the current intensive antineoplastic treatment regimens. There is optimism that the treatment of children who have advanced stage solid tumors with intensive, multimodality therapy may improve their chances for long-term survival. These treatment programs, though potentially curative, are highly toxic, with severe myelosuppression and damage to other organ systems. An awareness of these potential toxicities, an understanding of how to prevent or minimize certain problems, and the ability to treat those complications which do arise are all essential to the successful management of childhood cancer.
D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D003131:Combined Modality Therapy; D005767:Gastrointestinal Diseases / Q000209:etiology; D006331:Heart Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D007154:Immune System Diseases / Q000209:etiology; D007239:Infections / Q000209:etiology; D008171:Lung Diseases / Q000209:etiology; D009369:Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy*; D009422:Nervous System Diseases / Q000209:etiology; D009748:Nutrition Disorders / Q000209:etiology; D011832:Radiation Injuries; D014570:Urologic Diseases / Q000209:etiology
D000970:Antineoplastic Agents